Skip to main content

Table 3 Effectiveness clinical variables a

From: Pirfenidone gel in patients with localized scleroderma: a phase II study

Patient Initial mLoSSI Final mLoSSI Improvement mLoSSI (%) Mean basal durometer Mean final durometer Improvement durometer (%) Initial VAS hardness Final VAS hardness Improvement VAS hardness (%) Initial VAS pruritus Final VAS pruritus Improvement VAS pruritus (%)
1 1 0 100 56.73 49.12 13.41 0 4 −4 0 5 −5
2 3 0 100 35.6 34.51 3.06 0 0 0 0 0 0
3 14 6 57 36.95 38.09 −3.08 7 5 29 0 0 0
4 11 1 93 28.37 30.27 −6.7 8 2 75 7 2.5 65
5 9 0 100 33.71 31.14 7.62 5 3 40 8 3 62
6 3 0 100 26.21 27.03 −3.13 6.5 1.5 77 6.5 2 69
7 2 0 100 32.49 35.39 −8.93 10 4.5 55 5 2.5 50
8 2 1 50 30.23 26.26 13.13 5 3 40 0 0 0
9 4 2 50 45.52 42.02 7.69 7 3 57 5 2 60
10 3 0 100 42.68 35.29 17.31 8 0 100 5 0 100
11 14 0 100 36.83 27.05 26.56 0 0 0 3 0 100
12 4 0 100 24.18 13.51 44.12 3 3 0 8 0 100
Mean 5.83 0.83 NA 35.79 32.47 NA 4.96 2.42 NA 3.96 1.42 NA
P-valueb   0.002    0.05    0.032    0.065  
  1. aThe response to pirfenidone is evidenced by improvement in both physician (mLoSSI and durometer units) and patient (hardness of the lesions) evaluations. bWilcoxon rank-sum test. mLoSSI, Modified Localized Scleroderma Skin Severity Index; VAS, Visual analogue scale.